NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment, Study Finds
IRVINE, CA and AMSTERDAM – In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast Read More
Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment
IRVINE, CA and AMSTERDAM – In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular Read More
Agendia Co-Founder and CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer
IRVINE, CA and AMSTERDAM, July 31, 2014 – Innovative research by Rene Bernards, Ph.D., the co-founder of Agendia, Inc., has identified a gene signature that has potential to identify which patients will benefit from tamoxifen Read More
Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer
IRVINE, CA, AMSTERDAM and Rye Brook, N.Y., July 16, 2014 – Agendia, a leading molecular diagnostics company, and CBLPath, Inc., a leading pathology services provider, today announced they have agreed to collaborate in providing molecular Read More
Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 10, 2014 – There are substantial differences between the results provided by Agendia’s next-generation breast cancer tests and more limited results from the first-generation, 21-gene assay, according to Read More
African-American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer
Washington, D.C., June 9, 2014 – A research study led by cancer specialists at MedStar Washington Hospital Center found that African-American women frequently present with biologically less favorable subtypes of breast cancer. Researchers at the Read More
Multiple Studies on Agendia’s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 22, 2014– New research involving Agendia’s genomic tests MammaPrint®, BluePrint®, TargetPrint® and TheraPrint®, as well as its ColoPrint® Colon Cancer Genomic Profile, will be reported at the 2014 Read More
